{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:11:30Z","timestamp":1787508690868,"version":"build-2736575974"},"reference-count":45,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,8,11]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To comprehensively assess evidence on the measurement properties of the minimal disease activity (MDA) criteria, a composite measure of the state of disease activity in psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted literature review was conducted to identify studies that informed the validity and\/or ability of the MDA to detect change among patients known to have experienced a change in clinical status. The search was conducted using MEDLINE and Embase databases (published as of October 2017). Pertinent articles provided by investigators and identified from select conference proceedings were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 publications met the inclusion criteria. The MDA criteria were consistently associated with other indicators of disease activity\/severity. The ability of the MDA criteria to detect change was supported in randomised controlled trials (n=10), with a greater percentage of patients randomised to active treatments achieving MDA relative to patients in comparator arms. Long-term observational studies (n=2) provided additional support for the ability of the MDA to detect within-subject change in the real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence supports the MDA as a valid measure of disease activity in PsA that can detect between-group and within-subject change. The MDA is a comprehensive measure and clinically meaningful endpoint to assess the impact of interventions on PsA disease activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001002","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T07:45:11Z","timestamp":1567842311000},"page":"e001002","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Measurement properties of the minimal disease activity criteria for psoriatic arthritis"],"prefix":"10.1136","volume":"5","author":[{"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Immunology\/Rheumatology, Stanford University, Stanford, California, USA"},{"name":"Biopharmaceutical Consultant, Portola Valley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Wilson","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim, Ridgefield, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Revicki","sequence":"additional","affiliation":[{"name":"Evidera Inc, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Stolshek","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Samad","sequence":"additional","affiliation":[{"name":"Pharmaceutical Product Development, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Chung","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[{"name":"Medicine\/Rheumatology, Krembil Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"School of Medicine, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"2025090312040995000_5.2.e001002.1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312040995000_5.2.e001002.2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025090312040995000_5.2.e001002.3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312040995000_5.2.e001002.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"2025090312040995000_5.2.e001002.5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312040995000_5.2.e001002.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker349"},{"key":"2025090312040995000_5.2.e001002.7","doi-asserted-by":"crossref","unstructured":"Egeberg A , Khalid U , Gislason GH , et al . Association of psoriatic disease with uveitis: a Danish nationwide cohort study. JAMA Dermatol 2015;151.doi:10.1001\/jamadermatol.2015.1986","DOI":"10.1001\/jamadermatol.2015.1986"},{"key":"2025090312040995000_5.2.e001002.8","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol"},{"key":"2025090312040995000_5.2.e001002.9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5 Suppl 85","key":"2025090312040995000_5.2.e001002.10","article-title":"Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis","volume":"32","author":"Ferguson","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312040995000_5.2.e001002.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2025090312040995000_5.2.e001002.12","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090312040995000_5.2.e001002.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090312040995000_5.2.e001002.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312040995000_5.2.e001002.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160904"},{"key":"2025090312040995000_5.2.e001002.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090312040995000_5.2.e001002.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2025090312040995000_5.2.e001002.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090312040995000_5.2.e001002.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2025090312040995000_5.2.e001002.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2025090312040995000_5.2.e001002.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312040995000_5.2.e001002.22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2025090312040995000_5.2.e001002.23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312040995000_5.2.e001002.24","doi-asserted-by":"crossref","unstructured":"McHugh ML . Interrater reliability: the kappa statistic. Biochem Med 2012;22.","DOI":"10.11613\/BM.2012.031"},{"key":"2025090312040995000_5.2.e001002.25","doi-asserted-by":"crossref","unstructured":"Queiro R , Ca\u00f1ete JD , Montilla C , et al . Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 2017;19.doi:10.1186\/s13075-017-1277-1","DOI":"10.1186\/s13075-017-1277-1"},{"key":"2025090312040995000_5.2.e001002.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"2025090312040995000_5.2.e001002.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150165"},{"key":"2025090312040995000_5.2.e001002.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22576"},{"key":"2025090312040995000_5.2.e001002.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2025090312040995000_5.2.e001002.30","doi-asserted-by":"crossref","unstructured":"Coates L , Mease PJ , Gossec L , et al . Patients with active psoriatic arthritis achieving minimal disease activity with secukinumab treatment demonstrate sustained improvement of function and quality of life [abstract]. Arthritis Rheumatol 2016;68.","DOI":"10.1093\/rheumatology\/kex062.077"},{"key":"2025090312040995000_5.2.e001002.31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease","year":"2017","journal-title":"RMD Open"},{"key":"2025090312040995000_5.2.e001002.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2025090312040995000_5.2.e001002.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016619","article-title":"Real-World validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry","volume":"7","author":"Rahman","year":"2017","journal-title":"BMJ Open"},{"key":"2025090312040995000_5.2.e001002.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150595"},{"key":"2025090312040995000_5.2.e001002.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170112"},{"key":"2025090312040995000_5.2.e001002.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2025090312040995000_5.2.e001002.37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for research and assessment of psoriasis and psoriatic Arthritis\/Outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312040995000_5.2.e001002.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211998"},{"key":"2025090312040995000_5.2.e001002.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180249"},{"key":"2025090312040995000_5.2.e001002.40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11136-016-1449-5","article-title":"The impact of patient-reported outcome measures in clinical practice for pain: a systematic review","volume":"26","author":"Holmes","year":"2017","journal-title":"Qual Life Res"},{"key":"2025090312040995000_5.2.e001002.41","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312040995000_5.2.e001002.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312040995000_5.2.e001002.43","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"2025090312040995000_5.2.e001002.44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312040995000_5.2.e001002.45","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:04:22Z","timestamp":1756926262000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,6]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/rmdopen-2019-001002"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001002","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}